Atopic Dermatitis: Epidemiology Forecast to 2027

2018-11-27
Price :
Published : Nov-2018
No. of Pages : 30

Atopic Dermatitis: Epidemiology Forecast to 2027

Summary

Atopic dermatitis (AD) or atopic eczema is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Although the condition affects people of all ages, it is primarily common among infants and children. Modifiable risk factors include inhalant allergens, food allergens, and newborns not being exclusively breastfed, while non-modifiable risk factors include young age and genetics or heritability.

This epidemiology forecast for AD is supported by historical data obtained from peer-reviewed articles and population-based studies. These sources used questionnaires and various diagnostic measures to assess AD symptoms across the 7MM. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of AD across these markets.

In the 7MM, the one-year total prevalent cases of AD are expected to increase from 81,608,107 cases in 2017 to 83,639,767 cases in 2027, at an Annual Growth Rate (AGR) of 0.25%. In the 7MM, the one-year diagnosed prevalent cases of AD are expected to increase from 36,109,879 cases in 2017 to 36,873,084 cases in 2027, at an AGR of 0.21%. In 2027, the US will have the highest number of one-year diagnosed prevalent cases of AD in the 7MM with 18,236,642 diagnosed prevalent cases, whereas Germany will have the fewest number of one-year diagnosed prevalent cases with 1,797,130 cases.

Scope

– The Atopic Dermatitis (AD) Epidemiology Forecast Report provides an overview of the risk factors and global trends of AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– This report also includes a 10-year epidemiological forecast for the one-year total prevalent cases (both diagnosed and undiagnosed) and one-year diagnosed prevalent cases of AD segmented by sex, age, and severity (mild, moderate, and severe) in the 7MM.
– The Atopic Dermatitis epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Atopic Dermatitis (AD) Epidemiology Forecast report will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global AD market.
– Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
– Understand magnitude of AD population by severity and other clinically relevant segmentations.

Filed in: Pharmaceutical, Therapeutics
Publisher : GlobalData
More Reports
Title Price Buy Now

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products

Allergic Diseases: Pipeline Offers Novel Approaches to Treat Increasingly Prevalent Conditions, with Strong Presence of Cytokine Mediators Among First-in-Class Products Summary An allergy or allergic disease is a condition that arises from an adverse reaction to an exogenous antigen, a substance that invokes an immunological response. These conditions are extremely common. The number of people diagnosed with allergic diseases is rising rapidly on a global scale, which is attributable to factors such as population growth and increased urbanization and pollution. In addition, for a minority of these patients, allergic reactions can be severe, debilitating, or even life-threatening. Despite this high disease burden, treatment options are limited for many conditions and patients often recei......
$6995

Digital Therapeutics and Their Impact on Healthcare

Digital Therapeutics and Their Impact on Healthcare Summary Due to increasing levels in healthcare spending combined with declining R&D returns, digital therapeutics (DTx) represent a new way of treatment in which digital systems are used as regulatory?approved, to treat medical conditions as prescribed therapeutic interventions. There is a growing number of DTx developed on the market today as well as pipeline products in development following internationally-recognized, quality, design and manufacturing standards. DTx will provide a new approach to treatment and disease management in which patients have the possibility to learn more about their conditions and treatment options and this will lead to manage their own health and disease conditions. This report provides an overview of cur......
$7995

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends – Q1 2019

Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019 Summary GlobalData's "Pharmaceutical & Healthcare Quarterly Deals Analysis M&A and Investment Trends - Q1 2019", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2019. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information o......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Italy

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Italy. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Italy. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on th......
$3500

Down Syndrome Global Clinical Trials Review, H1, 2019

Down Syndrome Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Down Syndrome Global Clinical Trials Review, H1, 2019" provides an overview of Down Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical......
$2500

Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019

Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Endometrial Hyperplasia Global Clinical Trials Review, H1, 2019" provides an overview of Endometrial Hyperplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Endometrial Hyperplasia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma e......
$2500

Dermatomyositis Global Clinical Trials Review, H1, 2019

Dermatomyositis Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dermatomyositis Global Clinical Trials Review, H1, 2019" provides an overview of Dermatomyositis clinical trials scenario. This report provides top line data relating to the clinical trials on Dermatomyositis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019

Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2019" provides an overview of Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Dysbetalipoproteinemia (Type III Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on n......
$2500

Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019

Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019 Summary GlobalData's clinical trial report, "Diabetic Neuropathic Pain Global Clinical Trials Review, H1, 2019" provides an overview of Diabetic Neuropathic Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Neuropathic Pain. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy